Ketogenic Diet in the Treatment of Super-Refractory Status Epilepticus at a Pediatric Intensive Care Unit: A

Markus Breu1, Chiara Häfele1, Sarah Glatter1

  • 1Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Vienna, Austria.

Insights

The ketogenic diet (KD) showed a 50% initial response rate in treating super-refractory status epilepticus (SRSE) in pediatric patients. Early KD initiation and adequate ketosis levels were achieved, but overall survival remained poor due to severe underlying etiologies.

Area of Science:

  • Pediatric intensive care
  • Neurology
  • Nutritional science

Background:

  • Super-refractory status epilepticus (SRSE) is a severe condition requiring advanced treatment strategies.
  • The ketogenic diet (KD) is explored as an add-on therapy for SRSE after standard treatments fail.
  • Understanding KD's efficacy in pediatric SRSE is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the effectiveness of the ketogenic diet (KD) in treating super-refractory status epilepticus (SRSE) in a pediatric intensive care unit (PICU).
  • To analyze clinical and electroencephalographic (EEG) findings in pediatric SRSE patients treated with KD.
  • To determine the time to ketosis and response rates associated with KD therapy in this population.

Main Methods:

  • Retrospective analysis of eight pediatric patients with SRSE treated with KD.
  • Data collected from a prospective longitudinal KD database.
  • Response defined as EEG seizure resolution; ketosis defined as serum beta-hydroxybutyrate (BHB) >2 mmol/L.

Main Results:

  • Four out of eight (50%) pediatric patients with SRSE responded to KD treatment within seven days.
  • Median time to achieve clinically relevant ketosis was 68 hours.
  • Higher ketosis levels were associated with combined enteral and parenteral nutrition.
  • Despite initial response, five patients died within 3-12 months due to severe underlying etiologies.

Conclusions:

  • The ketogenic diet (KD) demonstrates an initial 50% response rate in pediatric super-refractory status epilepticus (SRSE).
  • Early KD administration and achieving adequate ketosis are feasible in SRSE management.
  • Severe underlying conditions significantly impact long-term survival despite KD treatment response.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
565
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
839
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
389
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
858
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
48
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
323